JP Morgan Maintains Overweight on Medline, Raises Price Target to $53
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $50 to $53.
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $50 to $53.